LINCOLN PHARMACEUTICALS
|
LINCOLN PHARMACEUTICALS Last 5 Year Balance Sheet History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr |
Equity - Authorised | ₹32 Cr | ₹32 Cr | ₹32 Cr | ₹32 Cr | ₹20 Cr |
Equity - Issued | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr |
Equity Paid Up | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹10.00 | ₹10.00 | ₹10.00 | ₹10.00 | ₹10.00 |
Share Warrants & Outstandings | - | - | - | - | - |
Total Reserves | ₹573 Cr | ₹482 Cr | ₹413 Cr | ₹346 Cr | ₹293 Cr |
Securities Premium | ₹65 Cr | ₹65 Cr | ₹65 Cr | ₹65 Cr | ₹65 Cr |
Capital Reserves | ₹-9.59 Cr | ₹-9.59 Cr | ₹-9.59 Cr | ₹-9.59 Cr | ₹0.35 Cr |
Profit & Loss Account Balance | ₹507 Cr | ₹418 Cr | ₹348 Cr | ₹282 Cr | ₹220 Cr |
General Reserves | ₹11 Cr | ₹10 Cr | ₹9.74 Cr | ₹9.24 Cr | ₹8.26 Cr |
Other Reserves | ₹-0.42 Cr | ₹-0.48 Cr | ₹-0.18 Cr | ₹-0.31 Cr | ₹-0.33 Cr |
Reserve excluding Revaluation Reserve | ₹573 Cr | ₹482 Cr | ₹413 Cr | ₹346 Cr | ₹293 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹593 Cr | ₹502 Cr | ₹433 Cr | ₹366 Cr | ₹313 Cr |
Minority Interest | - | - | - | - | ₹0.38 Cr |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | - | - | ₹0.15 Cr | ₹0.85 Cr |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | ₹0.15 Cr | ₹0.85 Cr |
Unsecured Loans | - | - | - | - | - |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | - |
Other Unsecured Loan | - | - | - | - | - |
Deferred Tax Assets / Liabilities | ₹11 Cr | ₹7.94 Cr | ₹6.46 Cr | ₹5.69 Cr | ₹5.43 Cr |
Deferred Tax Assets | ₹0.93 Cr | ₹0.71 Cr | ₹0.47 Cr | ₹0.77 Cr | ₹0.99 Cr |
Deferred Tax Liability | ₹12 Cr | ₹8.65 Cr | ₹6.93 Cr | ₹6.46 Cr | ₹6.43 Cr |
Other Long Term Liabilities | ₹3.63 Cr | ₹4.72 Cr | ₹4.54 Cr | ₹4.29 Cr | ₹4.05 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹0.10 Cr | ₹25 Cr | - | ₹16 Cr | ₹33 Cr |
Total Non-Current Liabilities | ₹15 Cr | ₹38 Cr | ₹11 Cr | ₹26 Cr | ₹43 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹72 Cr | ₹51 Cr | ₹72 Cr | ₹57 Cr | ₹51 Cr |
Sundry Creditors | ₹72 Cr | ₹51 Cr | ₹72 Cr | ₹57 Cr | ₹51 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹15 Cr | ₹15 Cr | ₹9.84 Cr | ₹13 Cr | ₹9.13 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | ₹1.32 Cr | ₹0.82 Cr | ₹0.11 Cr | ₹3.54 Cr | ₹1.53 Cr |
Interest Accrued But Not Due | - | - | - | - | ₹0.05 Cr |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹14 Cr | ₹14 Cr | ₹9.73 Cr | ₹9.89 Cr | ₹7.55 Cr |
Short Term Borrowings | ₹1.07 Cr | ₹2.00 Cr | ₹2.04 Cr | - | ₹3.83 Cr |
Secured ST Loans repayable on Demands | - | - | - | - | ₹3.83 Cr |
Working Capital Loans- Sec | - | - | - | - | ₹3.83 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | ₹1.07 Cr | ₹2.00 Cr | ₹2.04 Cr | - | ₹-3.83 Cr |
Short Term Provisions | ₹29 Cr | ₹29 Cr | ₹27 Cr | ₹24 Cr | ₹16 Cr |
Proposed Equity Dividend | - | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹25 Cr | ₹25 Cr | ₹24 Cr | ₹22 Cr | ₹16 Cr |
Provision for post retirement benefits | - | - | - | - | - |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹3.52 Cr | ₹3.89 Cr | ₹2.66 Cr | ₹2.18 Cr | ₹0.44 Cr |
Total Current Liabilities | ₹117 Cr | ₹96 Cr | ₹111 Cr | ₹95 Cr | ₹80 Cr |
Total Liabilities | ₹725 Cr | ₹637 Cr | ₹555 Cr | ₹487 Cr | ₹437 Cr |
ASSETS | |||||
Gross Block | ₹237 Cr | ₹197 Cr | ₹171 Cr | ₹142 Cr | ₹147 Cr |
Less: Accumulated Depreciation | ₹57 Cr | ₹47 Cr | ₹39 Cr | ₹31 Cr | ₹24 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹179 Cr | ₹151 Cr | ₹132 Cr | ₹111 Cr | ₹123 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹3.48 Cr | ₹6.71 Cr | ₹16 Cr | ₹1.69 Cr | ₹0.04 Cr |
Non Current Investments | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.09 Cr |
Long Term Investment | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.09 Cr |
Quoted | - | - | - | - | - |
Unquoted | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.09 Cr |
Long Term Loans & Advances | ₹71 Cr | ₹88 Cr | ₹32 Cr | ₹47 Cr | ₹51 Cr |
Other Non Current Assets | ₹0.00 Cr | ₹0.00 Cr | ₹1.75 Cr | ₹0.45 Cr | ₹0.04 Cr |
Total Non-Current Assets | ₹254 Cr | ₹245 Cr | ₹182 Cr | ₹160 Cr | ₹174 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | ₹139 Cr | ₹91 Cr | ₹97 Cr | ₹81 Cr | ₹34 Cr |
Quoted | ₹9.73 Cr | - | - | - | - |
Unquoted | ₹129 Cr | ₹91 Cr | ₹97 Cr | ₹81 Cr | ₹34 Cr |
Inventories | ₹77 Cr | ₹70 Cr | ₹73 Cr | ₹47 Cr | ₹47 Cr |
Raw Materials | ₹22 Cr | ₹21 Cr | ₹27 Cr | ₹18 Cr | ₹14 Cr |
Work-in Progress | ₹8.28 Cr | ₹9.18 Cr | ₹8.72 Cr | ₹5.53 Cr | ₹6.96 Cr |
Finished Goods | ₹7.61 Cr | ₹1.70 Cr | ₹2.04 Cr | ₹1.67 Cr | ₹7.27 Cr |
Packing Materials | ₹8.92 Cr | ₹9.25 Cr | ₹9.82 Cr | ₹6.77 Cr | ₹7.47 Cr |
Stores  and Spare | - | - | - | - | - |
Other Inventory | ₹30 Cr | ₹29 Cr | ₹25 Cr | ₹15 Cr | ₹12 Cr |
Sundry Debtors | ₹162 Cr | ₹136 Cr | ₹116 Cr | ₹113 Cr | ₹101 Cr |
Debtors more than Six months | ₹12 Cr | ₹6.99 Cr | ₹4.79 Cr | ₹11 Cr | - |
Debtors Others | ₹152 Cr | ₹131 Cr | ₹113 Cr | ₹104 Cr | ₹103 Cr |
Cash and Bank | ₹14 Cr | ₹34 Cr | ₹19 Cr | ₹14 Cr | ₹15 Cr |
Cash in hand | ₹0.56 Cr | ₹0.37 Cr | ₹0.25 Cr | ₹0.34 Cr | ₹0.40 Cr |
Balances at Bank | ₹13 Cr | ₹34 Cr | ₹19 Cr | ₹14 Cr | ₹14 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹1.69 Cr | ₹2.10 Cr | ₹1.19 Cr | ₹1.43 Cr | ₹1.11 Cr |
Interest accrued on Investments | - | - | - | - | - |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | ₹0.06 Cr | ₹0.14 Cr | ₹0.34 Cr | ₹0.21 Cr | - |
Prepaid Expenses | ₹1.63 Cr | ₹1.94 Cr | ₹0.37 Cr | ₹1.14 Cr | ₹1.09 Cr |
Other current_assets | - | ₹0.03 Cr | ₹0.48 Cr | ₹0.09 Cr | ₹0.03 Cr |
Short Term Loans and Advances | ₹79 Cr | ₹57 Cr | ₹68 Cr | ₹72 Cr | ₹64 Cr |
Advances recoverable in cash or in kind | ₹4.34 Cr | ₹2.10 Cr | ₹2.57 Cr | ₹15 Cr | ₹16 Cr |
Advance income tax and TDS | ₹25 Cr | ₹24 Cr | ₹20 Cr | ₹19 Cr | ₹15 Cr |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹49 Cr | ₹31 Cr | ₹45 Cr | ₹37 Cr | ₹34 Cr |
Total Current Assets | ₹472 Cr | ₹391 Cr | ₹373 Cr | ₹328 Cr | ₹263 Cr |
Net Current Assets (Including Current Investments) | ₹354 Cr | ₹295 Cr | ₹262 Cr | ₹233 Cr | ₹182 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹725 Cr | ₹637 Cr | ₹555 Cr | ₹487 Cr | ₹437 Cr |
Contingent Liabilities | ₹0.23 Cr | ₹0.23 Cr | ₹0.23 Cr | ₹1.46 Cr | ₹2.19 Cr |
Total Debt | ₹1.07 Cr | ₹2.00 Cr | ₹2.04 Cr | ₹0.52 Cr | ₹5.07 Cr |
Book Value | 295.98 | 250.86 | 216.12 | 182.92 | 156.54 |
Adjusted Book Value | 295.98 | 250.86 | 216.12 | 182.92 | 156.54 |
Compare Balance Sheet of peers of LINCOLN PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
LINCOLN PHARMACEUTICALS | ₹1,569.8 Cr | -3.8% | 24.7% | 31.4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
LINCOLN PHARMACEUTICALS | -3.8% |
24.7% |
31.4% |
SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses